Active Brain Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Brain Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Brain Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Brain Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Brain Cancer Clinical Trial FAQ

Are there clinical trials specifically for glioblastoma (GBM)?

Yes — glioblastoma is one of the most active areas of neuro-oncology research. Trials are testing novel immunotherapy approaches (CAR-T targeting EGFRvIII, IL13Rα2, and GD2), oncolytic viruses, convection-enhanced delivery of targeted agents, vaccine-based therapies, and combination approaches with tumor-treating fields (TTFields). Newly diagnosed and recurrent GBM are both enrolled in separate studies.

Does my IDH mutation status affect brain cancer trial eligibility?

Yes. IDH1 and IDH2 mutations define a biologically distinct subset of gliomas (grades 2–4). IDH inhibitors (olutasidenib, ivosidenib) are FDA-approved for other IDH-mutated cancers and are being studied in IDH-mutated glioma. Many glioma trials stratify or enroll separately based on IDH status, so knowing your mutation status is important.

Can patients with brain metastases (from another cancer) join brain cancer trials?

Trials specifically for brain metastases are available, separate from primary brain tumor trials. These enroll patients with brain metastases from lung cancer, breast cancer, melanoma, and other primaries. Eligibility typically requires stable brain metastases (not rapidly progressing) and sometimes a minimum size threshold for measurable disease.

How does MGMT methylation status affect glioblastoma trial eligibility?

MGMT promoter methylation predicts better response to temozolomide (the standard chemotherapy for GBM). Some trials enroll all GBM patients regardless of MGMT status, while others stratify or specifically target unmethylated tumors (which respond less well to standard treatment and may benefit most from a novel approach). Your neuro-oncologist can interpret your MGMT result.

How do I find a brain cancer trial near me, especially if I need to be close to home?

Enter your diagnosis and ZIP code on Trialify. We sort trial sites by distance so you can see which trials have centers nearby. Many neuro-oncology trials have sites at major cancer centers and university hospitals, but some community sites also participate. For patients who cannot travel, some trials offer remote monitoring between in-person visits.

Explore Other Cancer Trial Guides

• Glioblastoma (GBM) — Glioblastoma (GBM) is the most aggressive primary brain tumor. Trials are advancing immunotherapy, CAR-T cell therapy targeting EGFRvIII and GD2, tumor-treating fields (TTFields), oncolytic viruses, and convection-enhanced delivery of targeted agents for both newly diagnosed and recurrent GBM.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.